Celsion Corporation Announces DSMB has Confirmed Initial Safety of Weekly GEN-1 Dosing at 100 mg/m² in 15 Randomized Patients with Advanced Ovarian Cancer
February 06, 2020 09:25 ET
|
Celsion CORP
Phase 2 Portion Will Continue After Patients Have Completed Their Full Treatment Regimen of up to 17 doses of GEN-1 plus Standard Chemotherapy LAWRENCEVILLE, N.J., Feb. 06, 2020 (GLOBE...
PharmaCyte Biotech Will Have All the Protection It Needs for Pancreatic Cancer Treatment Upon Marketing Approval
February 04, 2020 09:00 ET
|
PharmaCyte Biotech
NEW YORK, NY, Feb. 04, 2020 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) is about to embark upon a planned U.S. FDA Phase 2b clinical trial to treat locally advanced, inoperable pancreatic...
AVRA Medical Robotics Clears Debt
February 03, 2020 11:46 ET
|
AVRA Medical Robotics, Inc.
ORLANDO, Fla., Feb. 03, 2020 (GLOBE NEWSWIRE) -- AVRA Medical Robotics, Inc. (the “Company”) (OTCQB: AVMR), a medical software and artificial intelligence company building a fully autonomous medical...
Drug Developers Are Making Strides in Streamlining Patient Recruitment and Retention for Clinical Trials, According to Tufts Center for the Study of Drug Development
January 28, 2020 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Efforts by drug developers during the last decade to improve recruitment and retention of patients for clinical trials appear to be paying off, as...
PharmaCyte Biotech’s Pancreatic Cancer Therapy Passes Critical FDA-Required Tests as Countdown to IND Submission Begins
January 27, 2020 09:00 ET
|
PharmaCyte Biotech
NEW YORK, NY, Jan. 27, 2020 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) announced that its clinical trial product, which will be employed during the company’s upcoming Phase 2b clinical...
Sorrento to Present Late Breaking Positive Clinical Trial Data for Resiniferatoxin at Two Prestigious Upcoming Pain Conferences
January 27, 2020 07:00 ET
|
Sorrento Therapeutics, Inc.
Phase 1b/2 OA Knee Pain study completed enrollment of 93 patients, with no dose limiting toxicities observed and significant efficacy signal confirmed in expansion cohorts. The program is expected to...
SINTX TECHNOLOGIES ANNOUNCES COMMENCEMENT OF RIGHTS OFFERING SUBSCRIPTION PERIOD
January 23, 2020 07:00 ET
|
SINTX Technologies, Inc.
SALT LAKE CITY, UT, Jan. 23, 2020 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an original equipment manufacturer (OEM) ceramics company that develops and...
Hemp, Inc. Praises Recently Announced Bi-partisan House Legislation That Promotes Hemp-Derived CBD as Dietary Supplement
January 21, 2020 08:00 ET
|
Hemp, Inc.
Las Vegas, NV, Jan. 21, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Hemp, Inc. (OTC PINK: HEMP), announced today its support of new bi-partisan House legislation that would promote hemp-derived CBD...
AVRA Medical Robotics Attends J.P. Morgan Healthcare Conference
January 17, 2020 13:10 ET
|
AVRA Medical Robotics, Inc.
ORLANDO, Fla., Jan. 17, 2020 (GLOBE NEWSWIRE) -- AVRA Medical Robotics, Inc. (the “Company”) (OTCQB: AVMR), a medical software and artificial intelligence company that is in the process of building...
PharmaCyte Biotech Addressing Unmet Need in Patients with LAPC as Pancreatic Cancer 5-Year Survival Rate Increases to 10%
January 14, 2020 09:00 ET
|
PharmaCyte Biotech
NEW YORK, NY, Jan. 14, 2020 (GLOBE NEWSWIRE) -- This month the American Cancer Society announced that for the first time ever, the 5-year survival rate for pancreatic cancer has reached double...